Empowering Sustained Cardiometabolic Health
At Rivus, we are focused on advancing cardiometabolic health by developing new oral medicines from our proprietary development platform. Our lead therapy HU6 is a potential best-in-class oral MASH therapy that is uniquely positioned to address the significant unmet needs in this chronic liver disease. HU6 is advancing in the ongoing AMPLIFY Phase 2 trial for MASH. Our pipeline also includes RV-8451, a highly-differentiated oral GLP-1, in IND-enabling studies for obesity.
Contact Us
For general inquiries please e-mail us at info@rivuspharma.com.